Immunovia AB (publ) (LON: 0G8X)
London
· Delayed Price · Currency is GBP · Price in SEK
0.489
-0.023 (-4.49%)
Jan 21, 2025, 8:07 AM BST
Immunovia AB Revenue
Immunovia AB had revenue of 235.00K SEK in the quarter ending September 30, 2024, a decrease of -51.84%. This brings the company's revenue in the last twelve months to 632.00K, down -67.10% year-over-year. In the year 2023, Immunovia AB had annual revenue of 1.58M with 37.55% growth.
Revenue (ttm)
632.00K SEK
Revenue Growth
-67.10%
P/S Ratio
n/a
Revenue / Employee
57.45K SEK
Employees
11
Market Cap
5.85M GBP
Revenue Chart
* This company reports financials in SEK.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 1.58M | 430.00K | 37.55% |
Dec 31, 2022 | 1.15M | 301.00K | 35.66% |
Dec 31, 2021 | 844.00K | 482.00K | 133.15% |
Dec 31, 2020 | 362.00K | 6.00K | 1.69% |
Dec 31, 2019 | 356.00K | 23.00K | 6.91% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AstraZeneca | 38.20B |
GSK plc | 31.31B |
Haleon | 11.24B |
Smith & Nephew | 4.46B |
ConvaTec Group | 1.74B |
Hikma Pharmaceuticals | 2.39B |
HUTCHMED (China) | 483.31M |
Oxford Nanopore Technologies | 167.75M |